Compared to Estimates, Pfizer (PFE) Q4 Earnings: A Look at Key Metrics

Pfizer (PFE) reported $17.76 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 24.7%. EPS of $0.63 for the same period compares to $0.10 a year ago.The reported revenue represents a surprise of +1.52% over the Zacks Consensus Estimate of $17.5 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +31.25%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Specialty Care- Cibinqo- United States: $29 million versus $25.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +45% change. Revenues- Primary Care- Eliquis alliance revenues and direct sales- United States: $1.13 billion compared to the $1.01 billion average estimate based on three analysts. The reported number represents a change of +21% year over year. Revenues- Oncology- Ibrance- Total International: $382 million versus the three-analyst average estimate of $377.09 million. The reported number represents a year-over-year change of -5.7%. Revenue- Specialty Care- Cibinqo- Total International: $35 million versus the three-analyst average estimate of $41.15 million. The reported number represents a year-over-year change of +94.4%. Revenues- Oncology- Ibrance- Worldwide: $1.10 billion versus $1.03 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.1% change. Revenue- Business Innovation- Pfizer Ignite: $26 million versus the three-analyst average estimate of $17.33 million. The reported number represents a year-over-year change of +30%. Revenues- Specialty Care- Xeljanz- Worldwide: $349 million compared to the $323.32 million average estimate based on three analysts. The reported number represents a change of -29.2% year over year. Revenues- Oncology- Inlyta- Worldwide: $242 million versus $240.85 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -8% change. Revenues- Oncology- Xtandi alliance revenues- United States: $565 million versus $563.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +79.9% change. Revenues- Oncology- Xtandi alliance revenues- Worldwide: $565 million compared to the $563.44 million average estimate based on three analysts. The reported number represents a change of +79.9% year over year. Revenues- Specialty Care- Inflectra- Worldwide: $127 million compared to the $113.39 million average estimate based on three analysts. The reported number represents a change of +8.6% year over year. Revenues- Primary Care- Eliquis alliance revenues and direct sales- Worldwide: $1.83 billion compared to the $1.66 billion average estimate based on three analysts. The reported number represents a change of +13.7% year over year. View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned -2.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks